Vicarius raises $21.8M in series A

Commercialization company Vicarius Pharma AG (Kuessnacht, Switzerland) raised $21.8 million in a series A round on Aug. 14. CEO of Patheon N.V. (NYSE:PTHN) James Mullen was an investor in the round, and is chairman of Vicarius' board.

The newco partners with U.S. biopharmas to commercialize their first products in the EU. Vicarius offers its partners regulatory, pricing and commercialization strategy advice. It also is responsible for obtaining European marketing authorization for partnered assets, and for related legal and operational obligations...